Okada H - Search Results

1

Anti-C5a complementary peptide ameliorates acute peritoneal injury induced by neutralization of Crry and CD59.

Mizuno T, Mizuno M, Imai M, Suzuki Y, Kushida M, Noda Y, Maruyama S, Okada H, Okada N, Matsuo S, Ito Y. Mizuno T, et al. Among authors: okada n, okada h. Am J Physiol Renal Physiol. 2013 Dec 1;305(11):F1603-16. doi: 10.1152/ajprenal.00681.2012. Epub 2013 Jul 31. Am J Physiol Renal Physiol. 2013. PMID: 23904221 Free article.

2

Soluble complement receptor type 1 protects rats from lethal shock induced by anti-Crry antibody following lipopolysaccharide priming.

Mizuno M, Nishikawa K, Okada N, Matsuo S, Okada H. Mizuno M, et al. Among authors: okada n, okada h. Int Arch Allergy Immunol. 2002 Jan;127(1):55-62. doi: 10.1159/000048169. Int Arch Allergy Immunol. 2002. PMID: 11893854

3

Anti-C5a complementary peptide mitigates zymosan-induced severe peritonitis with fibrotic encapsulation in rats pretreated with methylglyoxal.

Iguchi D, Mizuno M, Suzuki Y, Sakata F, Maruyama S, Okada A, Okada H, Ito Y. Iguchi D, et al. Among authors: okada a, okada h. Am J Physiol Renal Physiol. 2018 Dec 1;315(6):F1732-F1746. doi: 10.1152/ajprenal.00172.2018. Epub 2018 Oct 3. Am J Physiol Renal Physiol. 2018. PMID: 30280601 Free article.

4

CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9.

Farkas I, Baranyi L, Ishikawa Y, Okada N, Bohata C, Budai D, Fukuda A, Imai M, Okada H. Farkas I, et al. Among authors: okada n, okada h. J Physiol. 2002 Mar 1;539(Pt 2):537-45. doi: 10.1113/jphysiol.2001.013381. J Physiol. 2002. PMID: 11882685 Free PMC article.

5

Inactivation of C5a anaphylatoxin by a peptide that is complementary to a region of C5a.

Fujita E, Farkas I, Campbell W, Baranyi L, Okada H, Okada N. Fujita E, et al. Among authors: okada n, okada h. J Immunol. 2004 May 15;172(10):6382-7. doi: 10.4049/jimmunol.172.10.6382. J Immunol. 2004. PMID: 15128829

6

Increased inhibitory capacity of an anti-C5a complementary peptide following acetylation of N-terminal alanine.

Okada N, Asai S, Hotta A, Miura N, Ohno N, Farkas I, Hau L, Okada H. Okada N, et al. Among authors: okada h. Microbiol Immunol. 2007;51(4):439-43. doi: 10.1111/j.1348-0421.2007.tb03918.x. Microbiol Immunol. 2007. PMID: 17446684 Free article.

7

Novel complementary peptides to target molecules.

Okada H, Imai M, Ono F, Okada A, Tada T, Mizue Y, Terao K, Okada N. Okada H, et al. Among authors: okada n, okada a. Anticancer Res. 2011 Jul;31(7):2511-6. Anticancer Res. 2011. PMID: 21873168

8

Effects of human soluble thrombomodulin on experimental glomerulonephritis.

Ikeguchi H, Maruyama S, Morita Y, Fujita Y, Kato T, Natori Y, Akatsu H, Campbell W, Okada N, Okada H, Yuzawa Y, Matsuo S. Ikeguchi H, et al. Among authors: okada n, okada h. Kidney Int. 2002 Feb;61(2):490-501. doi: 10.1046/j.1523-1755.2002.00160.x. Kidney Int. 2002. PMID: 11849389 Free article.

9

Mouse complement receptor-related gene y/p65-neutralized tumor vaccine induces antitumor activity in vivo.

Ohta R, Kondor N, Dohi N, Tomlinson S, Imai M, Holers VM, Okada H, Okada N. Ohta R, et al. Among authors: okada n, okada h. J Immunol. 2004 Jul 1;173(1):205-13. doi: 10.4049/jimmunol.173.1.205. J Immunol. 2004. PMID: 15210776

10

Inhibition of HIV-1 infection in cells expressing an artificial complementary peptide.

Hosokawa M, Imai M, Okada H, Okada N. Hosokawa M, et al. Among authors: okada n, okada h. Biochem Biophys Res Commun. 2004 Nov 5;324(1):236-40. doi: 10.1016/j.bbrc.2004.09.038. Biochem Biophys Res Commun. 2004. PMID: 15465008

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,601 results

Search Page

Filters